Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
Aiming to be the first FDA-approved medication to treat suicidal depressionDesigned to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC)Completion
